Hemashield implantation in young patients with congenital cardiovascular lesions

Ryo Aeba, Toshiyuki Katogi, Shiaki Kawada

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


Background. There is substantial controversy regarding the use of Hemashield in young patients. Methods. Twenty-one consecutive patients younger than 20 years of age with a variety of congenital cardiovascular lesions underwent surgical procedures using a Hemashield woven graft. Hemashield was used for reconstruction of the aortic wall (n = 16), ventricular septum (n = 10), and right ventricular free wall or pulmonary artery (n = 6). Results. A sterile inflammatory reaction was observed including high fever, increased white cell count, and elevated plasma C- reactive protein concentration for up to 4 weeks after implantation. Multivariable analysis identified the use of Hemashield in the right ventricular free wall or pulmonary artery as an incremental risk factor for elevation of plasma C-reactive protein concentration during the first 3 weeks after implantation (p = 0.002). There were no midterm complications including restenosis of the grafts in the right ventricular outflow tract. Conclusions. Hemashield can be used in a variety of situations for reconstruction of congenital cardiovascular lesions in young patients. Impregnated collagen can cause a significant systemic inflammatory reaction for several weeks after implantation, especially when used in the low-pressure right heart. (C) 2000 by The Society of Thoracic Surgeons.

Original languageEnglish
Pages (from-to)1920-1924
Number of pages5
JournalAnnals of Thoracic Surgery
Issue number6
Publication statusPublished - 2000 Jun
Externally publishedYes

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Hemashield implantation in young patients with congenital cardiovascular lesions'. Together they form a unique fingerprint.

Cite this